Ascendis Pharma A/S Ordinary Share ASND
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T01:07:56.256Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:57:28.875996461Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T01:07:55.888984+00:00
Ascendis Pharma A/S Ordinary Share options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 279.34 | 40.1% | 6.5% | 245.09 | 60.1% | 8.4% |
| 25Δ | 276.56 | 39.3% | 5.7% | 248.12 | 64.3% | 7.7% |
| 30Δ | 273.78 | 38.5% | 4.8% | 251.38 | 67.1% | 6.9% |
| 35Δ | 271.00 | 37.7% | 4.0% | 254.99 | 67.9% | 6.1% |
| 40Δ | 268.72 | 37.6% | 3.5% | 258.61 | 68.6% | 5.3% |
| 45Δ | 266.71 | 37.8% | 3.1% | 262.25 | 69.2% | 4.7% |
| 50Δ | 264.71 | 38.0% | 2.7% | 265.92 | 69.7% | 4.0% |
| 55Δ | 262.70 | 38.2% | 2.3% | 269.58 | 70.3% | 3.4% |
| 60Δ | 260.69 | 38.4% | 1.9% | 274.29 | 73.8% | 3.0% |
| 65Δ | 279.14 | 77.6% | 2.6% | |||
| 70Δ | 286.74 | 86.6% | 2.3% | |||
| 75Δ | 298.38 | 102.1% | 2.1% | |||
| 80Δ | 320.66 | 130.5% | 2.0% | |||
20Δ
- Pseudo strike
- 279.34
- IV
- 40.1%
- B/E move
- 6.5%
- Pseudo strike
- 245.09
- IV
- 60.1%
- B/E move
- 8.4%
25Δ
- Pseudo strike
- 276.56
- IV
- 39.3%
- B/E move
- 5.7%
- Pseudo strike
- 248.12
- IV
- 64.3%
- B/E move
- 7.7%
30Δ
- Pseudo strike
- 273.78
- IV
- 38.5%
- B/E move
- 4.8%
- Pseudo strike
- 251.38
- IV
- 67.1%
- B/E move
- 6.9%
35Δ
- Pseudo strike
- 271.00
- IV
- 37.7%
- B/E move
- 4.0%
- Pseudo strike
- 254.99
- IV
- 67.9%
- B/E move
- 6.1%
40Δ
- Pseudo strike
- 268.72
- IV
- 37.6%
- B/E move
- 3.5%
- Pseudo strike
- 258.61
- IV
- 68.6%
- B/E move
- 5.3%
45Δ
- Pseudo strike
- 266.71
- IV
- 37.8%
- B/E move
- 3.1%
- Pseudo strike
- 262.25
- IV
- 69.2%
- B/E move
- 4.7%
50Δ
- Pseudo strike
- 264.71
- IV
- 38.0%
- B/E move
- 2.7%
- Pseudo strike
- 265.92
- IV
- 69.7%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- 262.70
- IV
- 38.2%
- B/E move
- 2.3%
- Pseudo strike
- 269.58
- IV
- 70.3%
- B/E move
- 3.4%
60Δ
- Pseudo strike
- 260.69
- IV
- 38.4%
- B/E move
- 1.9%
- Pseudo strike
- 274.29
- IV
- 73.8%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 279.14
- IV
- 77.6%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 286.74
- IV
- 86.6%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 298.38
- IV
- 102.1%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 320.66
- IV
- 130.5%
- B/E move
- 2.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 42.55% | |
| 41.46% | |
| 41.56% | |
| 43.35% | |
| 43.54% | |
| 43.23% | |
| 41.16% | |
| 40.52% | |
| 39.26% | |
| 41.10% |
Biotechnology
ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered…
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →AUTL
Description unavailable
More →AVBP
Description unavailable
More →